Vaxart, Inc. (VXRT)

Market Cap	85.50M
Revenue (ttm)	28.70M
Net Income (ttm)	-66.95M
Shares Out	227.95M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,655,189
Open	0.4035
Previous Close	0.4151
Day's Range	0.3702 - 0.4035
52-Week Range	0.2800 - 1.0700
Beta	1.28
Analysts	Strong Buy
Price Target	3.00 (+699.79%)
Earnings Date	May 13, 2025

About VXRT

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Steven Lo
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: VXRT
• Website: https://vaxart.com

Financial Performance

In 2024, Vaxart's revenue was $28.70 million, an increase of 288.94% compared to the previous year's $7.38 million. Losses were -$66.95 million, -18.82% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for VXRT stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 699.79% from the latest price.

Price Target

$3.0

(699.79% upside)

Analyst Consensus: Strong Buy